ACADIA Pharmaceuticals Inc. Profile Avatar - Palmy Investing

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the tr…
Biotechnology
US, San Diego [HQ]
Strategy & Leadership

Mergers & Acquisitions Beta

M&A Deals · Breakdown

ACADIA Pharmaceuticals Inc. has no acquisition track records yet.

M&A Deals · History

ACADIA Pharmaceuticals Inc. has no acquisition track records yet.

M&A Deals · Within Industry

No current deals within Biotechnology Industry.

M&A Deals · Latest

Act, dont react; Track the most urgent M&A deals across all industries

Details
Owens Corning
Debt
Agg. Maximum Price
$373,155,000.00
Details
?
Equity
Agg. Maximum Price
$n/a
Details
?
Equity
Agg. Maximum Price
$4,221.65
?
Details
?
Equity
Agg. Maximum Price
$2,264,484.00
Details
United Bankshares, Inc.
Equity
Agg. Maximum Price
$206,633,909.86
?
Details
?
Equity
Agg. Maximum Price
$381.73
Details
?
Equity
Agg. Maximum Price
$7,657,428.54
Details
Icahn Enterprises L.P.
Debt
Agg. Maximum Price
$700,000,000.00
?
Details
?
Equity
Agg. Maximum Price
$19,377,844.50
Details
Corebridge Financial, Inc.
Debt
Agg. Maximum Price
$500,000,000.00
End of ACAD's Analysis
CIK: 1070494 CUSIP: 004225108 ISIN: US0042251084 LEI: - UEI: -
Secondary Listings
ACAD has no secondary listings inside our databases.